SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that ...

Recent advances in defining low- and intermediate-risk myelodysplastic syndromes (MDSs) have emphasized the critical role of molecular characterization using next-generation sequencing (NGS).

I didn?t want to give the impression from my last two posts that it?s all RNAi all the time at this year?s Keystone Symposium on Epigenetics and Chromatin Remodeling in Development. Polycomb group ...

Fulcrum Therapeutics ’ pociredir, a polycomb repressive complex 2 (PRC2) inhibitor, is designed to induce expression of fetal hemoglobin to compensate for the mutated hemoglobin that occurs in SCD.

Polycomb proteins, which regulate the expression of key genes, are dysregulated in many human cancers. When these proteins are experimentally removed, the activity of the targeted genes is ...

PRC2.1 catalyzes the majority of H3K27me3 at Polycomb target genes and is sufficient to promote recruitment of CBX2/4-cPRC1 but not CBX7-cPRC1.

More information: Weiran Ge et al, Basis of the H2AK119 specificity of the Polycomb repressive deubiquitinase, Nature (2023). DOI: 10.1038/s41586-023-05841-y ...

Major histocompatibility complex class I (MHC-I) gene promoters are bivalently modified during development, which can be exploited in cancer cells to silence MHC-I expression and evade CD8+ T cells; ...

Keywords: polycomb, psychiatric disorder, pathogenesis, psychiatry, development Citation: Peedicayil J (2022) The relevance of polycomb group proteins to the development of psychiatric disorders.

PMID: 34312226; PMCID: PMC8346877. Yellajoshyula, D*, Abigail Rogers, Audrey J. Kim, Sumin Kim, Samuel S. Pappas and Dauer, William T*: A pathogenic THAP1 DYT6 dystonia mutation causes hypomyelination ...